Victor Kha, DO
Pulmonary Disease · Nashville, TNNPI 1396003356
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,900 of the $44,000 with a category attached, or 79.3%. AstraZeneca accounts for 87.2% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $23,196, more than ten times the $458 reported in 2019. Among pulmonary disease clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 120 payments — averaging $366.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$38K
- Intuitive Surgical$4K
- GSK$291
- Actelion Pharmaceuticals US, Inc.$207
- Covidien LP$157
- Boehringer Ingelheim$148
- plus $362 from 8 others
What the payments were for
- Speaking & faculty fees$34,90079%
- Travel & lodging$2,0475%
- Food & beverage$2,9657%
- Education$4,0889%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 64 | $38,363 |
| Intuitive Surgical | 8 | $4,471 |
| GSK | 13 | $291 |
| Actelion Pharmaceuticals US, Inc. | 9 | $207 |
| Covidien LP | 3 | $157 |
| Boehringer Ingelheim | 7 | $148 |
| Amgen | 2 | $145 |
| Insmed, Inc. | 4 | $65 |
| Advanced Respiratory, Inc | 3 | $47 |
| Mylan Specialty L.p. | 3 | $42 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| 3b Medical, Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $15 |
| Sanofi | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$37,313
- Da Vinci Surgical System$4,291
- TEZSPIRE$243
How this compares
$44,000 in reported general payments places this provider in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 22 | $284,588 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 302 | $271,855 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $25,775 |
| EliquisApixaban | 39 | $23,554 |
| Spiriva RespimatTiotropium Bromide | 23 | $19,596 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $12,666 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $6,753 |
| Wixela InhubFluticasone Propion/Salmeterol | 24 | $4,964 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 161 | $4,432 |
| Roflumilast | 51 | $2,638 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $2,270 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $2,055 |
| Ventolin HfaAlbuterol Sulfate | 21 | $1,493 |
| Asmanex HfaMometasone Furoate | 11 | $1,338 |
| Fluticasone Propionate | 30 | $1,225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $148 | $304,18445 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $291 | $284,521329 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $38,363 | $32,52859 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Nashville
- Lisa LancasterNashville$519K
- Otis RickmanNashville$392K
- Susan GarwoodNashville$343K
- Joao DeandradeNashville$245K
- Anna HemnesNashville$183K
- Bryan HayNashville$126K
- Karl KuhnNashville$106K
- Fabien MaldonadoNashville$83K
- Margaret SalisburyNashville$53K
- Jennifer DukeNashville$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.